Whalesbook
Haleon Expands in Asia with Shanghai Investment
Haleon PLC is strengthening its presence in Asia with a £65 million investment for a new oral health manufacturing plant in Shanghai. This strategic move aims to tap into growth opportunities in China, Haleon's second-largest market, and India. CEO Brian McNamara emphasized the importance of e-commerce, which represents about 40% of Haleon's China business, as key to its next phase of growth. The company plans to expand its product offerings, with bolt-on acquisitions continuing to be a priority. Last year, Haleon took full ownership of its joint venture with Tianjin TSKF Pharmaceutical Co. to broaden its over-the-counter drug distribution in China.
Sales Decline Amidst Mild Cold and Flu Season
This expansion comes as Haleon faces sales challenges, including a dip following an unusually mild cold and flu season. The company's full-year 2025 revenue was £11.03 billion, down 1.8% year-over-year and below previous forecasts. Full-year organic revenue growth stood at 3%, missing its medium-term target of 4-6%. A weak cold and flu season created a 1.5 percentage-point drag, particularly impacting respiratory health products, which saw sales fall 1.9%. However, core products like Sensodyne toothpaste and Advil painkillers showed strength despite inflation. Oral Health products performed well, with 7.9% organic growth in 2025. Haleon reported a full-year margin of 22.9% for 2025, beating analyst expectations.
Haleon's Valuation Compared to Peers
Haleon has a market capitalization of roughly $45.7 billion. Its Price-to-Earnings (P/E) ratio is between 20x and 28x. This valuation is seen as somewhat expensive next to peers like Henkel (15.4x P/E) and Unilever (about 20x P/E). It is in line with or better than the European Pharmaceuticals industry average of 22.8x and its own estimated fair P/E of 26.8x. Haleon's net profit margin is 13.81%, stronger than Unilever's 12.25%. However, its stock price has underperformed broader market benchmarks over the past year.
Challenges Ahead: Execution Risks Rise
Haleon's Shanghai investment comes amid a challenging business environment. The recent sales miss and a cautious 2026 organic sales growth forecast of 3-5% have raised concerns among analysts. Jefferies noted the guidance was lowered, suggesting potential underperformance. The impact of the mild cold and flu season was greater than expected, showing how vulnerable the company is to unpredictable demand changes. Further challenges include a weakening US consumer and slower growth in emerging markets like Brazil. While e-commerce is a growth driver in China, Haleon's heavy reliance on it also creates dependency on platforms and potential competition. Haleon's stock fell over 7% after its revenue miss and cautious guidance. Despite strong gross margin improvements and double-digit organic profit growth, the key risk is whether Haleon can translate these efficiencies into steady sales growth amid demand swings.
Analyst Views and Future Plans
Despite recent setbacks, analyst consensus for Haleon is a "Moderate Buy." Wall Street analysts set an average 12-month price target of about $12.33, indicating potential upside of around 20%. Ratings are mixed, with some analysts issuing "strong buy" recommendations and others holding "hold" or "sell" ratings. Haleon aims for high single-digit growth in adjusted operating profit for 2026. The company also plans £500 million in share buybacks in 2026 and has proposed a 2025 dividend of 7.1p per share. Haleon is sticking to its medium-term goal of 4-6% organic growth beyond 2026, depending on the success of its 'Win as One' strategy.